NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

Inclusion Criteria * Cognitive function scores consistent with amnestic mild cognitive impairment based on pre-screening evaluation; * age 60-90 years; * MMSE score \>24 at time of initial consent; Exclusion Criteria * blood chemistries indicative of abnormal renal, liver, thyroid and adrenal function; estimated glomerular filtration rate using the MDRD prediction equation must be \>30 ml/min/1.73 m2; * any clinically significant abnormal blood chemistry values as determined by the research nurse or NMPCC nurse practitioner; * major psychiatric disorder (e.g. schizophrenia, bipolar disorder, major depression within past two years); * neurological or autoimmune conditions affecting cognition (e.g. Parkinson's disease, epilepsy, multiple sclerosis, mild or severe traumatic brain injury, large vessel infarct); * concussion within last 2 years and ≥ 3 lifetime concussions; * current systemic medical illnesses (e.g. cardiovascular disease, cancer, renal failure); * prior history of any type of cancer; * substance abuse or dependence (DSM-V criteria); * current use of medications used to treat dementia (e.g., anticholinesterase drugs) or other drugs likely to affect cognition (e.g., anticholinergic drugs, long-acting benzodiazepines); * claustrophobia, metal implants, pacemaker or other factors affecting feasibility and/or safety of MRI scanning\*; * current smoking (including marijuana) within the past 3 months; * hospitalization as a result of COVID-19